Robinson Capital Management’s Drugs Made In America Acquisition Corp Units DMAAU Stock Holding History

Robinson Capital Management’s Portfolio DMAAU Stock Details DMAAU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-30,000	Closed	-$315K	–	143
2025 Q4	$315K	Hold	30,000	–	–	0.13%	78
2025 Q3	$314K	Hold	30,000	–	–	0.17%	60
2025 Q2	$310K	Buy	+30,000	New	+$307K	0.13%	75

Other funds holding DMAAU

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Robinson Capital Management's DMAAU Position: Q1 2026 in Review

Robinson Capital Management sold out of Drugs Made In America Acquisition Corp Units (DMAAU) in Q1 2026, closing a stake of 30,000 shares — an estimated $315K sold.

Robinson Capital Management first reported a position in DMAAU in Q2 2025 and held it in 3 quarters. The position peaked at $315K in Q4 2025. 2 funds tracked by Wall St. Rank hold DMAAU as of Q1 2026.

Robinson Capital Management reported no remaining Drugs Made In America Acquisition Corp Units position as of Q1 2026 after selling out during the quarter.
Robinson Capital Management sold 30,000 Drugs Made In America Acquisition Corp Units shares in Q1 2026, an estimated $315K.
Robinson Capital Management first reported a position in Drugs Made In America Acquisition Corp Units in Q2 2025 and held it in 3 quarters.
Robinson Capital Management's Drugs Made In America Acquisition Corp Units position peaked at $315K in Q4 2025.
2 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Units as of Q1 2026.

Based on Robinson Capital Management's 13F filing for Q1 2026, filed 11 May 2026.